RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and development focus. The report includes information on current developmental pipeline.

1. RnR Market Research Offers “Lee’s Pharmaceutical Holdings Limited – Product Pipeline
Review – 2012” Report at US$ 1500 (Single User License). The report got published in Nov
2012 & contains 80 pages.
Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012
Summary
RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline
Review – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and development
focus. The report includes information on current developmental pipeline, complete with latest updates, and
features on discontinued and dormant projects.
This report is built using data and information sourced from RnR Market Research proprietary databases,
Lee’s Pharmaceutical Holdings Limited’s corporate website, SEC filings, investor presentations and featured
press releases, both from Lee’s Pharmaceutical Holdings Limited and industry-specific third party sources,
put together by RnR Market Research team.
Scope
 Lee’s Pharmaceutical Holdings Limited – Brief Lee’s Pharmaceutical Holdings Limited overview
including business description, key information and facts, and its locations and subsidiaries.
 Review of current pipeline of Lee’s Pharmaceutical Holdings Limited human therapeutic division.
 Overview of pipeline therapeutics across various therapy areas.
 Coverage of current pipeline molecules in various stages of drug development, including the
combination treatment modalities, across the globe.
 Product profiles for late stage and clinical stage products of Lee’s Pharmaceutical Holdings Limited
with complete description of the product’s developmental history, mechanism of action, therapeutic
class, target and major milestones.
 Recent updates of the Lee’s Pharmaceutical Holdings Limited’s pipeline in the last quarter.
 Key discontinued and dormant projects.
 Latest news and deals relating to the products.
Get your report copy of this report @ http://www.rnrmarketresearch.com/the-chinese-rd-landscape-
chemical-engineering-2-market-report.html
Reasons to buy
 Evaluate Lee’s Pharmaceutical Holdings Limited’s strategic position with total access to detailed
information on its product pipeline.
 Assess the growth potential of Lee’s Pharmaceutical Holdings Limited in its therapy areas of focus.
 Identify new drug targets and therapeutic classes in the Lee’s Pharmaceutical Holdings Limited’s
R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
 Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
 Exploit collaboration and partnership opportunities with Lee’s Pharmaceutical Holdings Limited.

2.  Avoid Intellectual Property Rights related issues.
 Explore the dormant and discontinued projects of Lee’s Pharmaceutical Holdings Limited and
identify potential opportunities in those areas.
Table Of contents
Table of Contents 2
List of Tables 6
List of Figures 6
Lee's Pharmaceutical Holdings Limited Snapshot 7
Lee's Pharmaceutical Holdings Limited Overview 7
Key Information 7
Key Facts 7
Lee's Pharmaceutical Holdings Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Lee's Pharmaceutical Holdings Limited - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance 14
Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline 14
Registration Filed Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Lee's Pharmaceutical Holdings Limited Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products 18
Pre-Clinical Products/Combination Treatment Modalities 18
Lee's Pharmaceutical Holdings Limited - Drug Profiles 19
Acetylcarnitine 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Declotana 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
istaroxime 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
JX-594 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levocarnitine propionate hydrochloride 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NOV-205 26
Product Description 26
Mechanism of Action 26
R&D Progress 26

3. paroxetine hydrochloride 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
procarbazine hydrochloride 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
prulifloxacin 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RGN-137 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RGN-259 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RGN-352 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
rostafuroxin 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
treprostinil 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ZK-002 39
Product Description 39
Mechanism of Action 41
R&D Progress 41
ZK-006 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ZK-008 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ZK007 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Lee's Pharmaceutical Holdings Limited - Pipeline Analysis 45
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Therapeutic Class 45
Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 46
Lee's Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action 47

4. Lee's Pharmaceutical Holdings Limited - Recent Pipeline Updates 48
Lee's Pharmaceutical Holdings Limited - Dormant Projects 53
Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries 54
Head Office 54
Lee's Pharmaceutical Holdings Limited, Recent Developments 55
Lee's Pharmaceutical Holdings Limited- Press Release 55
Jul 31, 2012: Lee's Pharma Enrolls First Patient In Phase Ib/IIa Clinical Study Of Anfibatide To Treat Acute
Coronary Syndrome 55
Jun 28, 2012: Lee's Pharma Completes Phase III Clinical Study Of L-Carnitine In Chronic Heart Failure
Patients 56
Financial Deals Landscape 57
Lee's Pharmaceutical Holdings Limited, Deals Summary 57
Lee's Pharmaceutical Holdings Limited, Pharmaceuticals & Healthcare, Deal Details 59
Asset Transactions 59
Powder Pharma And Lee's Pharma Acquire Rights & Related Assets Of Zingo From Anesiva 59
Partnerships 61
Lee's Pharma Enters Into Distribution Agreement With CID 61
United Therapeutics Enters Into Distribution Agreement With Lee's Pharma 63
Leepharm Enters Into Co-Marketing Agreement With Italfarmaco 65
Lee's Pharma Holdings Enters Into Distribution Agreement With Helsinn 66
Lee's Pharma Enters Into Distribution Agreement With Italfarmaco 67
Lee's Pharma Enters Into Distribution Agreement With APOGEPHA 68
Licensing Agreements 69
RegeneRx Biopharma Enters Into Licensing Agreement With Lee's Pharma For RGN-259, RGN-352 And
RGN-137 69
PLx Pharma Enters Into Licensing Agreement With Lee's Pharma For Cardiovascular Product 72
Recordati Enters Into Licensing Agreement With Lee's Pharma 73
Jennerex Enters Into Collaboration And License Agreement With Lee's Pharma Holdings 74
Nippon Shinyaku Enters Into Licensing Agreement With Lee's Pharma Holding 75
Anesiva Enters Into An Agreement With Lee's Pharma 76
Novelos Therapeutics Enters Into Licensing Agreement With Lee's Pharma 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 80
Disclaimer 80
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
Website: http://www.rnrmarketresearch.com/